Pralatrexate
Angioimmunoblastic T-Cell Lymphoma
Corvus Pharmaceuticals, Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 81/ 100
Competitive context
51 Active assets in the Angioimmunoblastic T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isocyclophosphamide Shandong Provincial Hospital | Phase 4 | BBB |
Dexasone Ou Bai, MD/PHD | Phase 2 | BB |
Prednisone Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
Etoposide Eric Jacobsen, MD | Phase 4 | BB |
Azacitidine National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Pralatrexate is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →Nodal T-follicular helper cell lymphoma, follicular typeActive
BB
Indicative · Phase 3
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →